| abstract |
The invention refers to a process for obtaining a pharmaceutical composition based on a gemotherapy extract of Corylus avellana enriched with chrysin/cyclodextrin nanocomplexes intended for liver fibrosis in diabetes. The process, according to the invention, consists of the following steps: obtaining the hemotherapy extract of Corylus avellana from fresh hazelnut buds in a solvent mixture of glycerine-ethyl alcohol 96% vol (1:1), by cold extraction, by maceration, time for 20 days, at a 1:20 plant-solvent ratio, the formulation of chrysin-cyclodextrin inclusion complexes, the mixing of the hemotherapy hazelnut extract with chrysin/cyclodextrin nanocomplexes and the lyophilization of the mixture, resulting in a phytotherapeutic composition with liver anti-fibrotic properties. |